BridgeBio Pharma Is Maintained at Outperform by Evercore ISI Group
Evercore Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $50
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
Optimistic Buy Rating for BridgeBio Pharma Due to Strong Launch and Strategic Initiatives
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $49
BridgeBio Pharma Analyst Ratings
BridgeBio Pharma's Growth Prospects Bolstered by Acoramidis Approval and Promising Pipeline
Bridgebio Pharma Says Committee For Medicinal Products For Human Use (CHMP) Recommends Marketing Authorization In European Union For Acoramidis For The Treatment Of Wild-type Or Variant Transthyretin Amyloidosis In Adult Patients With Cardiomyopathy...
Express News | EMA's Chmp: Adopted Positive Opinion for Beyonttra (Acoramidis)
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Disc Medicine (IRON) and BridgeBio Pharma (BBIO)
Unnatural Products Announces BridgeBio Exercises Option To License Macrocyclic Peptide Candidates Discovered Using UNP's AI-Enabled Massively Parallel Chemistry Platform
Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
Trending Stocks Today | Ambarella Surges 24.58% Post-Market
November 26th - US stocks trending post-market.Gainers: $Ambarella(AMBA.US)$ shoots up 24.58% to $85.23 with a turnover of $17.9 million. $Nutanix(NTNX.US)$ up 7.69% to $77.92 with a turnover of $20.1
BridgeBio Selects PANTHERx Rare Specialty Pharmacy for Distribution of Attruby (Acoramidis)
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $45 to $55
Scotiabank Maintains Sector Outperform on BridgeBio Pharma, Raises Price Target to $48
12 Health Care Stocks Moving In Monday's Pre-Market Session
BridgeBio Pharma Up Over 16%, on Pace for Largest Percent Increase Since July 2023 -- Data Talk
Orsini Chosen by BridgeBio as a Specialty Pharmacy Provider for ATTRUBY (Acoramidis), for the Treatment of Cardiomyopathy of Transthyretin-Mediated Amyloidosis
No Data